Dolores Isla

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Oncology, Standard Chemotherapy, Randomised Phase 3 +8

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

Rafael Rosell, Teresa Morán, Cristina Queralt et al. · New England Journal of Medicine · 2009 · 2.4K citations · Full text

A variant associated with nicotine dependence, lung cancer and peripheral arterial disease

Thorgeir E. Thorgeirsson, Frank Geller, Patrick Sulem et al. · Nature · 2008 · 1.5K citations

Tobacco Cessation, Tobacco Control, Tobacco Use +10

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Mary O’Brien, Luis Paz‐Ares, Sandrine Marréaud et al. · The Lancet Oncology · 2022 · 696 citations

Interim Analysis, Surgical Oncology, Oncology +8

Sequence variants at the TERT-CLPTM1L locus associate with many cancer types

Patrick Sulem, Simon Stacey, Frank Geller et al. · Nature Genetics · 2009 · 608 citations · Full text

Somatic Variant, Sequence Variants, Tumor Heterogeneity +11